Cadiz Inc. (CDZI) Shareholder/Analyst Call Prepared Remarks Transcript
Cadiz Inc. (CDZI) Shareholder/Analyst Call Prepared Remarks Transcript
Cadiz (CDZI) Reports Q3 Loss, Beats Revenue Estimates
Cadiz (CDZI) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.12 per share a year ago.
Cadiz (CDZI) Reports Q2 Loss, Lags Revenue Estimates
Cadiz (CDZI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
New Strong Sell Stocks for July 17th
FNF, MOH and CDZI have been added to the Zacks Rank #5 (Strong Sell) List on July 17, 2025.
Cadiz (CDZI) Reports Q1 Loss, Misses Revenue Estimates
Cadiz (CDZI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.12 per share a year ago.
Will Cadiz (CDZI) Report Negative Q1 Earnings? What You Should Know
Cadiz (CDZI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cadiz: Are The Preferreds Back In Play?
Cadiz is facing intense free cash burn as its plan to extract water from an aquifer in California faces environmental opposition. The Mojave Groundwater Bank project faces an uncertain future, with no clear pathway yet to come online. Common shareholders face continued dilution, while the preferreds offer a 12.8% yield on cost.
Top 3 Utilities Stocks That May Rocket Higher This Quarter
The most oversold stocks in the utilities sector presents an opportunity to buy into undervalued companies.
Cadiz (CDZI) Reports Q4 Loss, Misses Revenue Estimates
Cadiz (CDZI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology.
Recent Price Trend in Cadiz (CDZI) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cadiz (CDZI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Cadiz (CDZI) Reports Q3 Loss, Misses Revenue Estimates
Cadiz (CDZI) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.12 per share a year ago.
